119 related articles for article (PubMed ID: 38872014)
1. Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study.
Abe M; Yamaguchi T; Koshiba S; Takayama S; Nakai T; Nishioka K; Yamasaki S; Kawaguchi K; Umeyama M; Masaura A; Ishizawa K; Arita R; Kanno T; Akaishi T; Miyazaki M; Abe T; Tanaka T; Ishii T;
Clin Exp Nephrol; 2024 Jun; ():. PubMed ID: 38872014
[TBL] [Abstract][Full Text] [Related]
2. Reno-protective effects of oral alkalizing agents in chronic kidney disease with aciduria: protocol for a randomized cohort study.
Abe M; Akaishi T; Shoji M; Yamaguchi T; Miki T; Satoh F; Takayama S; Yamasaki S; Kawaguchi K; Sato H; Ishii T; Ito S;
BMC Nephrol; 2020 Apr; 21(1):144. PubMed ID: 32321450
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bicarbonate on Net Acid Excretion, Blood Pressure, and Metabolism in Patients With and Without CKD: The Acid Base Compensation in CKD Study.
Tyson CC; Luciano A; Modliszewski JL; Corcoran DL; Bain JR; Muehlbauer M; Ilkayeva O; Pourafshar S; Allen J; Bowman C; Gung J; Asplin JR; Pendergast J; Svetkey LP; Lin PH; Scialla JJ
Am J Kidney Dis; 2021 Jul; 78(1):38-47. PubMed ID: 33810868
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium bicarbonate supplementation on the renin-angiotensin system in patients with chronic kidney disease and acidosis: a randomized clinical trial.
Bovée DM; Roksnoer LCW; van Kooten C; Rotmans JI; Vogt L; de Borst MH; Zietse R; Danser AHJ; Hoorn EJ
J Nephrol; 2021 Oct; 34(5):1737-1745. PubMed ID: 33382448
[TBL] [Abstract][Full Text] [Related]
5. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
6. Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT.
Witham MD; Band M; Chong H; Donnan PT; Hampson G; Hu MK; Littleford R; Lamb E; Kalra PA; Kennedy G; McNamee P; Plews D; Rauchhaus P; Soiza RL; Sumukadas D; Warwick G; Avenell A
Health Technol Assess; 2020 Jun; 24(27):1-90. PubMed ID: 32568065
[TBL] [Abstract][Full Text] [Related]
7. Sodium citrate versus sodium bicarbonate for metabolic acidosis in patients with chronic kidney disease: A randomized controlled trial.
Sorohan BM; Obrișcă B; Jurubiță R; Lupușoru G; Achim C; Andronesi A; Frățilă G; Berechet A; Micu G; Ismail G
Medicine (Baltimore); 2024 Mar; 103(10):e37475. PubMed ID: 38457574
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study.
Di Iorio BR; Bellasi A; Raphael KL; Santoro D; Aucella F; Garofano L; Ceccarelli M; Di Lullo L; Capolongo G; Di Iorio M; Guastaferro P; Capasso G;
J Nephrol; 2019 Dec; 32(6):989-1001. PubMed ID: 31598912
[TBL] [Abstract][Full Text] [Related]
9. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
Kittiskulnam P; Srijaruneruang S; Chulakadabba A; Thokanit NS; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Am J Nephrol; 2020; 51(1):24-34. PubMed ID: 31752000
[TBL] [Abstract][Full Text] [Related]
10. Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.
Singh P; Vaughan LE; Schulte PJ; Sas DJ; Milliner DS; Lieske JC
Am J Kidney Dis; 2022 Sep; 80(3):373-382. PubMed ID: 35306035
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
Peng Z; Wang J; Yuan Q; Xiao X; Xu H; Xie Y; Wang W; Huang L; Zhong Y; Ao X; Zhang L; Zhao M; Tao L; Zhou Q;
BMC Nephrol; 2017 Oct; 18(1):311. PubMed ID: 29029600
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).
Gaggl M; Cejka D; Plischke M; Heinze G; Fraunschiel M; Schmidt A; Hörl WH; Sunder-Plassmann G
Trials; 2013 Jul; 14():196. PubMed ID: 23826760
[TBL] [Abstract][Full Text] [Related]
13. Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study.
Jacobson MH; Wu Y; Liu M; Attina TM; Naidu M; Karthikraj R; Kannan K; Warady BA; Furth S; Vento S; Trachtman H; Trasande L
PLoS Med; 2020 Oct; 17(10):e1003384. PubMed ID: 33052911
[TBL] [Abstract][Full Text] [Related]
14. Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis.
Goraya N; Simoni J; Sager LN; Madias NE; Wesson DE
Kidney Int; 2019 May; 95(5):1190-1196. PubMed ID: 30846270
[TBL] [Abstract][Full Text] [Related]
15. Risk factor for progression to kidney failure with replacement therapy in elderly patients with chronic kidney disease: A retrospective single-centre cohort study.
Nagae H; Ueno Y; Shojima M; Takae K; Kuroki Y; Katafuchi R
Nephrology (Carlton); 2023 Jun; 28(6):336-344. PubMed ID: 37086149
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.
Melamed ML; Horwitz EJ; Dobre MA; Abramowitz MK; Zhang L; Lo Y; Mitch WE; Hostetter TH
Am J Kidney Dis; 2020 Feb; 75(2):225-234. PubMed ID: 31699517
[TBL] [Abstract][Full Text] [Related]
17. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
18. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.
Zhang JJ; Yu GZ; Zheng ZH; Liu YF; Du YY; Quan SX; Liu YJ; Lv JC; Zhang H
PLoS One; 2017; 12(4):e0175828. PubMed ID: 28414748
[TBL] [Abstract][Full Text] [Related]
19. Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.
Provenzano M; Chiodini P; Minutolo R; Zoccali C; Bellizzi V; Conte G; Locatelli F; Tripepi G; Del Vecchio L; Mallamaci F; Di Micco L; Russo D; Heerspink HJL; De Nicola L
Nephrol Dial Transplant; 2020 Jan; 35(1):138-147. PubMed ID: 30053127
[TBL] [Abstract][Full Text] [Related]
20. Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status.
Berni E; Pritchard N; Jenkins-Jones S; Ambery P; Jain M; Jermutus L; Scott LA; Currie CJ
Endocrinol Diabetes Metab; 2018 Oct; 1(4):e00029. PubMed ID: 30815560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
